An In Vivo Inflammatory Loop Potentiates KRAS Blockade

KRAS (KRAS proto-oncogene, GTPase) inhibitors perform less well than other targeted drugs in vitro and fail clinical trials. To investigate a possible reason for this, we treated human and murine tumor cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isop...

Descripción completa

Detalles Bibliográficos
Autores principales: Arendt, Kristina A. M., Ntaliarda, Giannoula, Armenis, Vasileios, Kati, Danai, Henning, Christin, Giotopoulou, Georgia A., Pepe, Mario A. A., Klotz, Laura V., Lamort, Anne-Sophie, Hatz, Rudolf A., Kobold, Sebastian, Schamberger, Andrea C., Stathopoulos, Georgios T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945202/
https://www.ncbi.nlm.nih.gov/pubmed/35327394
http://dx.doi.org/10.3390/biomedicines10030592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945202/
https://www.ncbi.nlm.nih.gov/pubmed/35327394
http://dx.doi.org/10.3390/biomedicines10030592

Ejemplares similares